SS28, a SRT501 analog with oral bioavailability, inhibits tubulin polymerization to cause cell cycle arrest at G2/M phase. SS28 results in apoptosis rather than necrosis tubulin[1].
in vivo
SS28 (15 mg/kg. b.wt.) treatment results in inhibition of tumor cell proliferation[1].
Animal Model:
BALB/c mice using EAC cells[1].
Dosage:
15 mg/kg.
Administration:
Orally on every alternate day for 9 doses.
Result:
There was no further tumor progression in the mice when SS28 was administered, unlike the untreated tumor control mice.
References
[1] Thomas E, et al. A Novel Resveratrol Based Tubulin Inhibitor Induces Mitotic Arrest and Activates Apoptosis in Cancer Cells. Sci Rep. 2016 Oct 17;6:34653. DOI:10.1038/srep34653
